S&P Global: Part B Changes May Affect Pharma Less Than Other Reforms

S&P Global Ratings analysts predicted that the Trump administration’s recent proposals on drug pricing would negatively impact pharmaceutical companies’ profit margins, but that international reference pricing in Medicare Part B likely would not result in ratings changes. In a commentary published Wednesday , analysts focused on administration proposals to stop rebates to pharmacy benefit managers, mandate direct-to-consumer advertising price disclosure, and use international reference pricing for drugs in Medicare Part B. The commentary concluded that while some companies may benefit...